Recently, the ClarIDHy trial, a phase 3 multicenter randomized study, tested the efficacy of the IDH1 inhibitor Ivosidenib in patients with pretreated, non resectable or metastatic CCA with IDH1 mutation, observing an improvement in PFS compared to placebo (mOS 2.7 months vs 1.4 months respectively) (11). The gene discussed is IDH1; the disease is cholangiocarcinoma.